Source comparison
CJC-1295 No DAC Animal vs Human Research — Key Differences
Research published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 No DAC produced mean growth hormone pulse amplitudes 3.2-fold higher in rodent models than in Phase I human trials at equivalent dosing per kilogram. That's not a roun
This comparison does not assign a generated winner or score.
- Research published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 No DAC produced mean growth hormone pulse amplitudes 3.2-fold higher in rodent models than in Phase I human trials at equivalent dosing per kilogram. That's not a rounding error. It's a fundamental divergence in how this peptide behaves across species, and it's the reason direct extrapolation from animal data creates unrealistic expectations about human outcomes.
- Our team has spent years evaluating research-grade peptides across both pre-clinical and clinical contexts. The gap between what animal studies suggest and what human trials deliver isn't about peptide purity. It's about receptor density, hepatic clearance rates, and species-specific feedback loops that govern GH secretion.
- What is the difference between CJC-1295 No DAC animal research and human research?
- Animal studies of CJC-1295 No DAC consistently show higher growth hormone pulse amplitude, faster onset of peak GH elevation (15–30 minutes vs 60–90 minutes in humans), and longer duration of detectable GH elevation (4–6 hours in rodents vs 2–3 hours in humans). Human trials demonstrate more modest GH increases, greater inter-individual variability, and hepatic first-pass metabolism effects absent in many animal models. The pharmacokinetic half-life in rats is approximately 30 minutes; in humans, it extends to 6–8 days, fundamentally altering dosing frequency and receptor saturation dynamics.